TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14697160
Drug: piperacillin/tazobactam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin/tazobactam (4 g/8 h iv)
Study: 14697160
Drug: ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftriaxone (2 g/24 h iv) plus ornidazole (1 g/24 h iv)
Study: 10579472
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride (500 mg) plus ketoconazole (100 mg twice daily for 3 days)
Study: 10579472
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride (500 mg) plus fluvoxamine (25 mg twice daily for 2 days)
Study: 2047064
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (25-mg tablets orally every 8 hours for 72 hours)
Study: 27338807
Drug: Lemborexant (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (2.5 to 75 mg) administered for 14 consecutive nights
Study: 27338807
Drug: Lemborexant (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (2.5, 10, or 25 mg) administered for 14 consecutive nights
Study: 26637091
Drug: Baroreflex sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex sensitivity test (BRS) in supine position (L-BRS)
Study: 20110022
Drug: Atorvastatin/Fenofibrate FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin/Fenofibrate FDC (40 mg/100 mg)
Study: 20110022
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg
Study: 15623686
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg CAB once daily
Study: 15623686
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg CAB once daily
Study: 15623686
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg CAB once daily
Study: 15623686
Drug: CAB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB therapy (mean dose of 2.2 mg per day over 1 year)
Study: 11242379
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with distraction and fusion using Harrington rods
Study: 9260078
Drug: Cola at
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cola at 33 mg/serving
Study: 9260078
Drug: Coffee at
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee at 33 mg/serving
Study: 9260078
Drug: Cola at
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cola at 100 mg/serving
Study: 9260078
Drug: Coffee at
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee at 100 mg/serving
Study: 8501457
Drug: Buprenorphine 6
Normalized name: buprenorphine 6.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 6 mg
Study: 8501457
Drug: Methadone 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 35 mg
Study: 8501457
Drug: Methadone 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 65 mg
Study: 10799369
Drug: EPA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (4 g daily)
Study: 24355229
Drug: Inhaled crenotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled crenotherapy with salso-sulphide water
Study: 18003666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of folic acid (2.5 mg), vitamin B6 (50 mg), and vitamin B12 (1 mg) daily for 5 years
Study: 18003666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of folic acid, vitamin B6, and vitamin B12
Study: 15910349
Drug: S-ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.2 mg.kg‐1 bolus followed by 5 microg.kg‐1.min‐1 infusion)
Study: 12909221
Drug: GEM CCRT
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM CCRT (600 mg/m(2)/wk for 6 weeks)
Study: 12909221
Drug: 5-FU CCRT
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU CCRT (500 mg/m(2)/d for 3 days repeated every 2 weeks for 6 weeks)
Study: 6666215
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (50‐200 micrograms/kg/h)
Study: 6666215
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide (1 mg/kg)
Study: 31931250
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg slow pumping dose, maintained at 0.3 μg/kg·h intraoperatively)
Study: 31931250
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (same amount as dexmedetomidine, same infusion method)
Study: 29410607
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention (MTSZ) group, received a 1-month music intervention series combined with antipsychotic drugs
Study: 29410607
Drug: No-music intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-music intervention (UMTSZ) group, treated solely with antipsychotic drugs
Study: 24302681
Drug: Pregnenolone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (400 mg)
Study: 21081550
Drug: varespladib methyl
Normalized name: Varespladib methyl
DrugBank: Varespladib methyl (DB05737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varespladib methyl 500 mg once daily
Study: 21081550
Drug: varespladib methyl
Normalized name: Varespladib methyl
DrugBank: Varespladib methyl (DB05737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varespladib methyl 250 mg once daily
Study: 16189179
Drug: l-arginine/GHRP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/GHRP-2
Study: 16189179
Drug: l-arginine/GHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/GHRH
Study: 12574185
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg/d)
Study: 12574185
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (patch delivering 50 microg/d)
Study: 8889112
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (group 1, n = 27)
Study: 8889112
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (group 2, n = 34)
Study: 6339923
Drug: Acyclovir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (200 mg per dose) five times daily for 10 days
Study: 30503296
Drug: Helical IMRT-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helical IMRT-based stereotactic body radiotherapy (SBRT) at dose levels 3-4 (42-60 Gy)
Study: 22260307
Drug: Anterior suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior suspension and posterior reconstruction during RALP (group B)
Study: 19499849
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg/die and gamma-linolenic acid (GLA) 360 mg/die
Study: 19499849
Drug: Multivitamin B
Normalized name: Avobenzone 2.5 mL in 125 mL / Octinoxate 9.4 mL in 125 mL / Octisalate 6.25 mL in 125 mL / Oxybenzone 3.75 mL in 125 mL TOPICAL LOTION [Multivitamin Bodyblock SPF 20]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin B preparation (Vit B6 150 mg, Vit B1 100 mg, Vit B12 500 microg daily)
Study: 19499849
Drug: Multivitamin B
Normalized name: Avobenzone 2.5 mL in 125 mL / Octinoxate 9.4 mL in 125 mL / Octisalate 6.25 mL in 125 mL / Oxybenzone 3.75 mL in 125 mL TOPICAL LOTION [Multivitamin Bodyblock SPF 20]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin B preparation
Study: 24890138
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg
Study: 16366763
Drug: Cocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (100 mg)
Study: 11519636
Drug: Cocaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (200 mg)
Study: 16366763
Drug: Cocaine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0 mg)
Study: 12169865
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg or 400 mg
Study: 8641325
Drug: Buffered sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered sublingual captopril (pH 7)
Study: 8641325
Drug: Unbuffered sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbuffered sublingual captopril
Study: 8641325
Drug: Buffered and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered and unbuffered sublingual captopril
Study: 25840296
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia associated with cryoanalgesia
Study: 21739693
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (Simo Decoction oral solution, three times daily for 10 days)
Study: 10434237
Drug: Azithromycin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1200 mg)
Study: 25709054
Drug: Daily Undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Undulating Progression (DUP)
Study: 23588309
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin once daily for 7 days
Study: 16841662
Drug: Pricking collateral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pricking collateral blood therapy (PCBT) combined with massage therapy
Study: 19148112
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy alone
Study: 12434720
Drug: Intravenous argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous argatroban infused at a rate of 1.25 micrograms/kg/min for 100 hours
Study: 12434720
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 7.5-mg dose of warfarin
Study: 12434720
Drug: Argatroban administered
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban administered alone
Study: 12434720
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of argatroban and warfarin
Study: 12434720
Drug: Argatroban administered
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban administered alone or with warfarin
Study: 8560532
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over 3 days)
Study: 9707362
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg per 8 hourly for 5 days)
Study: 368538
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of prazosin
Study: 368538
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of hydrallazine
Study: 23010344
Drug: Tanezumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (20 mg, single intravenous dose)
Study: 9830646
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing silicon dioxide, aloe vera, and allantoin
Study: 9830646
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel with silicon dioxide
Study: 9830646
Drug: Gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel with all 3 active substances
Study: 30928954
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg once daily
Study: 19332985
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery)
Study: 19332985
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron protein succinylate (80 mg/day)
Study: 19332985
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron protein succinylate
Study: 16785154
Drug: CC/hMG/cetrorelix protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/hMG/cetrorelix protocol
Study: 15472846
Drug: Guideline implementation
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline implementation for the treatment of CAP
Study: 11041314
Drug: Acute hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Acute hydrocortisone (100 mg, orally 11 h before)
Study: 11041314
Drug: Chronic hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chronic hydrocortisone (20 mg twice a day for 1 week)
Study: 9309369
Drug: Ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 400 mg o.d.
Study: 9309369
Drug: Amoxicillin/clavulanate (AMX/CA)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (AMX/CA) 500 mg/125 mg t.i.d.
Study: 2939862
Drug: Atracurium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.3 mg kg‐1
Study: 2939862
Drug: Suxamethonium 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.6 mg kg‐1 plus infusion
Study: 31285357
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control (TC) strategy with adalimumab (40 mg sc)
Study: 20667854
Drug: Epidural cortical
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural cortical stimulation during intensive speech-language therapy
Study: 20667854
Drug: Intensive speech-language
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive speech-language therapy without epidural stimulation (Control)
Study: 10027447
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 31) with targeted oxygen delivery index (DO2I) value of > 600 mL/min/m2
Study: 10027447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 32) with conventional therapy and normal targeted oxygen delivery
Study: 10027447
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 31)
Study: 1675225
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (bolus injection)
Study: 6185041
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg base per body weight every eight hours for 14 days (Group I)
Study: 6185041
Drug: Quinine adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine adjusted to body surface area based on an adult dose of 500 mg base eight hourly for 14 days (Group II)
Study: 15323576
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine 4mg
Study: 15323576
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous apomorphine injections
Study: 15323576
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous apomorphine infusions
Study: 11731749
Drug: Mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.5 g.kg‐1 as bolus at the start of skin incision, and postoperatively 0.5 g.kg‐1 daily three times a day for 3 days (72 hrs)
Study: 11731749
Drug: Mannitol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.25 g.kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml.h‐1 intraoperatively and mannitol 0.25 g.kg‐1 daily three times a day for 3 days plus HTS in the concentration of 3% in the first day and 2% and 1% the second and the third day after surgery
Study: 11731749
Drug: 3% HTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% HTS 3.5 ml kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml hr‐1 intraoperatively and 3% HTS, 20 ml h‐1 on the first day and 2% and 1% the second and the third day after surgery
Study: 11731749
Drug: Mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.5 g.kg‐1 and Mannitol 0.25 g.kg‐1
Study: 9165314
Drug: Objective group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective group (passing the 12 mm barium pill test)
Study: 9165314
Drug: Pill test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill test (overall correlation)
Study: 9165314
Drug: Passing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passing the pill test 1 week after dilation
Study: 9165314
Drug: Failing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failing the pill test
Study: 3593990
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens with tamoxifen 20 mg bid for patients with positive estrogen receptor status
Study: 28104469
Drug: 3-month intensive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month intensive lifestyle intervention consisting of weekly health education and 3 moderate-to-vigorous physical activity sessions/week
Study: 26206644
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo injection)
Study: 2537787
Drug: Kabi 2165,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2165, 2,500 anti‐Xa units twice a day (group A)
Study: 2537787
Drug: Kabi 2165,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2165, 2,500 anti‐Xa units twice a day during the first 48 h postoperatively and then 5,000 anti‐Xa units once a day (group B)
Study: 2537787
Drug: Adjusted-dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose standard heparin, monitored by activated partial thromboplastin time (group C)
Study: 31850603
Drug: Nicotine-replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-replacement therapy (NRT)
Study: 29099972
Drug: Subanesthetic dose
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic dose of ketamine
Study: 26665676
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dapoxetine on demand
Study: 26665676
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sertraline qd for one month
Study: 23702146
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling plus administration of a commercially available Ca(2+) and VitD supplementation product
Study: 11396283
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume BAL (mean volume: 131 +/- 14 ml)
Study: 11396283
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume BAL (40 ml volume for all patients)
Study: 8143994
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran supplement (13-15 g for 8 weeks)
Study: 8143994
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran supplement (13-15 g for 8 weeks)
Study: 8143994
Drug: Corn bran
Normalized name: CORN BRAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn bran supplement (13-15 g for 8 weeks)
Study: 2306750
Drug: Flunarizine 10-15
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10-15 mg (mean dose of 13 mg)
Study: 2306750
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg (single dose)
Study: 6254720
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intravenous clonidine after pretreatment with 300 mg cimetidine
Study: 6254720
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intravenous clonidine after pretreatment with 0.8 mg naloxone
Study: 6254720
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intravenous clonidine after pretreatment with saline
Study: 27224454
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) regimens for prevention of mother-to-child transmission during breastfeeding
Study: 25012765
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg/day in 3 divided doses) + Raloxifene (120 mg/day)
Study: 25012765
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg/day in 3 divided doses) + Placebo
Study: 17909753
Drug: Butorphanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0, 6, or 12 mg/70 kg, i.m.)
Study: 17909753
Drug: Naltrexone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0, 1, 3, 10, or 30 mg, p.o.)
Study: 16441799
Drug: lignocaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 5% spray
Study: 1451713
Drug: DoBe (L-Dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: DoBe (L-Dopa + benserazide)
Study: 1451713
Drug: DoBeBro (L-Dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: DoBeBro (L-Dopa + benserazide + bromocriptine)